Gelan has once again exceeded the 100 billion mark at the scale, and the net value growth rate of the management fund in the second quarter is as high as 14%

With the disclosure of the financial report of the public fund in the second quarter of 2022, the public fund manager's positioning, positioning paths, and performance of the public fund managers have emerged one after another. The net value also rebounded in the second quarter.

Choice data shows that as of the end of the second quarter of 2022, a total of 5 products in Gram Management Fund were Mixed Medical Health (A/C), China -Europe Medical Innovation Stocks (A/C), and China -Europe Alpha Mixed (A/C) The new starting point of the China -Europe Research Selection (A/C), and the new starting point of China Europe, the total management scale was 101.751 billion yuan, an increase of 5.6 billion yuan from the end of the first quarter.

Among them, China -Europe Medical Health Hybrid A (003095) increased the largest growth in the second quarter, an increase of 1.774 billion yuan during the period, and the latest scale reached 32.586 billion yuan. Increased to 38.496 billion yuan.

In terms of performance, the financial report shows that Gram's pipeline products have received positive income in the second quarter of 2022. Among them, the new starting point mixed (001000) performance of the new starting point in China is the best performance, and the net value of the second quarter increased by 14.04%. As of the end of the second quarter of 2022, the top ten heavy stocks of the new starting point (001000) of China Ou Mingrui were: Longji Green Energy, Ningde Times, Ensijie, Jing'ao Technology, Yimei Lithium, BYD, Sunshine Power, Godcrey, Godcrey Materials, Jinlang Technology, and Pai Tailai, holding a total of 58.17%. During the reporting period, Gelan has increased its holdings of new energy stocks such as Longji Green Energy, Jing'ao Technology, Tianci Materials, Yimei Lithium Energy, and Sunshine Power. It also jumped to the largest heavy position.

Chart source: choice data

Central Europe Alpha Mixed A (009776), Central Europe Alpha Mixed C (009777), China -EU Research Selected Mixed A (011435), and China -Europe Research Selected Mixed C (011436) period of net value increased by more than 10%, which were 13.85%and 13.70 respectively %,,0.40%, 10.18%. In addition, China -Europe Medical Health Hybrid A (003095), China -Europe Medical Health Hybrid C (003096), China -Europe Medical Innovation Stock A (006228), and China -Europe Medical Innovation Stock C (006229) have a net value of more than 4%during the reporting period.

- END -